CTRI/2009/091/000281Other2 期
A Phase II Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator Study Evaluating the Efficacy and Safety of PF-04523655 Versus Laser Therapy (DEGAS)
试验速览
- 阶段
- 2 期
- 状态
- Other
- 发起方
- Pfizer
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Ages Eligible for Study: 18 Years and older,
- •Genders Eligible for Study: Both,
- •Accepts Healthy Volunteers: No,
- •Patients with Diabetes Mellitus (Type 1 or Type 2) Showing Diabetic Macular Edema in the Eye.
排除标准
- •Proliferative Diabetic Retinopathy in the Study Eye. Subjects Receiving Concomitant Intravitreal Anti-VEGF Therapy.
研究者
相似试验
已完成
不适用
A Phase II Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator Study Evaluating The Efficacy And Safety Of PF-04523655 Versus Laser Therapy (DEGAS)-H36-E103 Insulin-dependent diabetes mellitus, with ophthalmic complications-E113 Non-insulin-dependent diabetes mellitus, with ophthalmic complicationsInsulin-dependent diabetes mellitus, with ophthalmic complicationsNon-insulin-dependent diabetes mellitus, with ophthalmic complicationsE103E113H36PER-153-08PFIZER S.A.,
招募中
2 期
inezolid Dosing Strategies in DR-TB.A150 Tuberculosis of lung, confirmed by sputum microscopy with or without cultureTuberculosis of lung, confirmed by sputum microscopy with or without cultureA150PER-014-22Instituto Nacional de Alergias y Enfermedades Infecciosas NIAID8
进行中（未招募）
不适用
Study on the effect of vitamin D in women at high risk of developing breast cancer.Women at high risk of developing breast cancerEUCTR2011-002162-21-ESJosé Esteban Castelao Fernández
已完成
2 期
A clinical study to determine safety, tolerability and efficacy of drug called Evenamide which is taken orally, in patients with long standing schizophrenia getting inadequate benefit from their current antipsychotic medication.CTRI/2021/04/032772ewron Pharmaceuticals SpA112
已完成
2 期
A clinical study to determine safety, tolerability and efficacy of drug called Evenamide which is taken orally, in patients with long standing schizophrenia getting inadequate benefit from their current antipsychotic medication.CTRI/2020/02/023099ewron Pharmaceuticals SpA111